These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 26187742)

  • 1. Head and Neck Hyperpigmentation Probably Associated with Polymyxin B Therapy.
    Zavascki AP; Manfro RC; Maciel RA; Falci DR
    Ann Pharmacother; 2015 Oct; 49(10):1171-2. PubMed ID: 26187742
    [No Abstract]   [Full Text] [Related]  

  • 2. Intravenous polymyxin B for the treatment of nosocomial pneumonia caused by multidrug-resistant Pseudomonas aeruginosa.
    Furtado GH; d'Azevedo PA; Santos AF; Gales AC; Pignatari AC; Medeiros EA
    Int J Antimicrob Agents; 2007 Oct; 30(4):315-9. PubMed ID: 17631984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymyxin B versus other antimicrobials for the treatment of pseudomonas aeruginosa bacteraemia.
    Kvitko CH; Rigatto MH; Moro AL; Zavascki AP
    J Antimicrob Chemother; 2011 Jan; 66(1):175-9. PubMed ID: 20961911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skin hyperpigmentation following intravenous polymyxin B treatment associated with melanocyte activation and inflammatory process.
    Mattos KPH; Cintra ML; Gouvêa IR; Ferreira LÁ; Velho PENF; Moriel P
    J Clin Pharm Ther; 2017 Oct; 42(5):573-578. PubMed ID: 28497462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histopathological findings of pigmented lesion and recovery of natural skin colour in a patient with polymyxin B-associated diffuse hyperpigmentation.
    Zavascki AP; Schuster LF; Duquia RP
    Int J Antimicrob Agents; 2016 Nov; 48(5):579-580. PubMed ID: 27720305
    [No Abstract]   [Full Text] [Related]  

  • 6. Polymyxin B-induced skin hyperpigmentation: a rare case report and literature review.
    Zheng G; Cao L; Che Z; Mao E; Chen E; He J
    BMC Pharmacol Toxicol; 2018 Jul; 19(1):41. PubMed ID: 29973293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymyxin B Induced Generalized Hyperpigmentation in Neonates.
    Gothwal S; Meena K; Sharma SD
    Indian J Pediatr; 2016 Feb; 83(2):179-80. PubMed ID: 26088547
    [No Abstract]   [Full Text] [Related]  

  • 8. Class I integron-borne bla(VIM-1) carbapenemase in a strain of Enterobacter cloacae responsible for a case of fatal pneumonia.
    Perilli M; Mezzatesta ML; Falcone M; Pellegrini C; Amicosante G; Venditti M; Stefani S
    Microb Drug Resist; 2008 Mar; 14(1):45-7. PubMed ID: 18321204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Necrotizing pneumonia following cardiac surgery in a neonate.
    Al Tassan RS; Al Alola S; Al Shaalan H; Al Saleh S
    J Infect Public Health; 2013 Jun; 6(3):154-7. PubMed ID: 23668457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymyxin B-induced skin hyperpigmentation.
    Li YM; Milikowski C; Selvaggi G; Abbo LM; Skiada D; Galimberti F
    Transpl Infect Dis; 2020 Oct; 22(5):e13312. PubMed ID: 32386075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Analysis of clinical features and outcome of nosocomial pneumonia caused by Pseudomonas aeruginosa].
    Baĭgozina EA
    Klin Med (Mosk); 2009; 87(6):57-9. PubMed ID: 19670720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acquired skin hyperpigmentation following intravenous polymyxin B treatment: a cohort study.
    Mattos KP; Lloret GR; Cintra ML; Gouvêa IR; Betoni TR; Mazzola PG; Moriel P
    Pigment Cell Melanoma Res; 2016 May; 29(3):388-90. PubMed ID: 26909746
    [No Abstract]   [Full Text] [Related]  

  • 13. Polymyxin B clinical outcomes: A prospective study of patients undergoing intravenous treatment.
    Mattos KPH; Gouvêa IR; Quintanilha JCF; Cursino MA; Vasconcelos PENS; Moriel P
    J Clin Pharm Ther; 2019 Jun; 44(3):415-419. PubMed ID: 30666679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the duration of antibiotics on clinical events in patients with Pseudomonas aeruginosa ventilator-associated pneumonia: study protocol for a randomized controlled study.
    Bouglé A; Foucrier A; Dupont H; Montravers P; Ouattara A; Kalfon P; Squara P; Simon T; Amour J;
    Trials; 2017 Jan; 18(1):37. PubMed ID: 28114979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antipseudomonic effect of macrolides. Experience in a case of nosocomial pneumonia caused by multidrug-resistant Pseudomonas aeruginosa without response to antibiotic therapy].
    Barbero JM; Arranz A; Rebollar A; Culebras A; García M; Agudo R; Pérez L; Montero E
    Rev Esp Quimioter; 2018 Feb; 31(1):72-74. PubMed ID: 29390604
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin.
    Hamer DH
    Am J Respir Crit Care Med; 2000 Jul; 162(1):328-30. PubMed ID: 10903263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical analysis of 60 cases of nosocomal pneumonias].
    Yu L; Chen YL; Zhu YJ
    Zhonghua Jie He He Hu Xi Za Zhi; 1994 Oct; 17(5):303-4, 320. PubMed ID: 7712575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Higher incidence of neurotoxicity and skin hyperpigmentation in renal transplant patients treated with polymyxin B.
    Zhou Y; Li Y; Xie X; Song L; Lan G; Sun B; Tang T; Yan H; Zhang B; Xu P
    Br J Clin Pharmacol; 2022 Nov; 88(11):4742-4750. PubMed ID: 35508710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Trends in the treatment of pneumonia].
    Grassi V; Romanelli G
    Recenti Prog Med; 1999; 90(7-8):373-9. PubMed ID: 10429515
    [No Abstract]   [Full Text] [Related]  

  • 20. Salvage treatment of pneumonia and initial treatment of tracheobronchitis caused by multidrug-resistant Gram-negative bacilli with inhaled polymyxin B.
    Pereira GH; Muller PR; Levin AS
    Diagn Microbiol Infect Dis; 2007 Jun; 58(2):235-40. PubMed ID: 17350201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.